Literature DB >> 8070143

Enhancing role of complement in HIV infection.

A Mouhoub1, N Thieblemont, C Delibrias, E Fischer, M D Kazatchkine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8070143      PMCID： PMC1550363          DOI： 10.1111/j.1365-2249.1994.tb06255.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  28 in total

1.  Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.

Authors:  T Hidvégi; Z Prohászka; E Ujhelyi; N M Thielens; M P Dierich; H Hampl; G Arlaud; K Nagy; G Füst
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

2.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

3.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

4.  Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV.

Authors:  V Boyer; C Delibrias; N Noraz; E Fischer; M D Kazatchkine; C Desgranges
Journal:  Scand J Immunol       Date:  1992-12       Impact factor: 3.487

5.  Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.

Authors:  G Poli; A L Kinter; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

6.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

7.  Complement activation by gp160 glycoprotein of HIV-1.

Authors:  N Thieblemont; N Haeffner-Cavaillon; L Weiss; F Maillet; M D Kazatchkine
Journal:  AIDS Res Hum Retroviruses       Date:  1993-03       Impact factor: 2.205

8.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).

Authors:  D C Montefiori; K Stewart; J M Ahearn; J Zhou; J Zhou
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.

Authors:  C C Delibrias; M D Kazatchkine; E Fischer
Journal:  Scand J Immunol       Date:  1993-08       Impact factor: 3.487

10.  Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins.

Authors:  J S Haurum; S Thiel; I M Jones; P B Fischer; S B Laursen; J C Jensenius
Journal:  AIDS       Date:  1993-10       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.